Pneumonia — Expected Recovery vs Treatment Failure

Antibiotic selection for community-acquired pneumonia (CAP) is guided by severity, setting of care, and risk factors for resistant organisms. The goal is to cover the most likely pathogens without unnecessary broad-spectrum therapy.

Outpatient CAP in a previously healthy patient without recent antibiotic use: amoxicillin 1 g three times daily is first-line for typical bacterial pneumonia. Doxycycline is an alternative that also covers atypical organisms (Mycoplasma, Chlamydophila, Legionella). Azithromycin monotherapy is appropriate only in areas with low macrolide resistance and in patients without significant comorbidities.

Outpatient CAP with comorbidities (COPD, diabetes, heart failure, liver disease, renal disease, asplenia, immunosuppression, or recent antibiotic use): combination therapy with amoxicillin-clavulanate or a cephalosporin plus a macrolide, or monotherapy with a respiratory fluoroquinolone (levofloxacin, moxifloxacin). Respiratory fluoroquinolones cover both typical and atypical organisms and are appropriate for patients who cannot tolerate beta-lactams.

Hospitalized non-ICU CAP: beta-lactam (ampicillin-sulbactam, ceftriaxone, or cefotaxime) plus a macrolide, or a respiratory fluoroquinolone alone. The combination regimen is preferred for patients with severe CAP or Legionella risk factors.

Hospitalized ICU CAP: beta-lactam plus azithromycin or a respiratory fluoroquinolone. Add MRSA coverage (vancomycin or linezolid) for patients with risk factors: prior MRSA infection, recent hospitalization, IV drug use, or cavitary infiltrates. Add Pseudomonas coverage (piperacillin-tazobactam, cefepime, or meropenem) for patients with structural lung disease, recent broad-spectrum antibiotic use, or healthcare-associated pneumonia.

Duration: 5 days is appropriate for most outpatient CAP that responds to treatment. Hospitalized CAP is typically treated for 5–7 days. Legionella and Pseudomonas pneumonia may require longer courses. The decision to stop antibiotics should be based on clinical response — not a fixed duration.

Understanding the expected recovery timeline for pneumonia prevents premature antibiotic changes and unnecessary additional testing in patients who are actually improving. The clinical course of community-acquired pneumonia follows a predictable pattern when the correct antibiotic is started.

Fever typically resolves within 2–4 days of starting appropriate antibiotic therapy. Leukocytosis normalizes within 3–5 days. Oxygen requirements improve within 3–5 days in most patients. Clinical symptoms (dyspnea, cough, fatigue) improve over 5–7 days. Radiographic infiltrates lag significantly behind clinical improvement — they can persist for 4–6 weeks, particularly in elderly patients and those with underlying lung disease.

The most important clinical marker of recovery is the patient's overall trajectory: improving dyspnea, decreasing oxygen requirements, defervescence, and improved functional status. A patient who is clinically improving but still has a fever on day 2 or a persistent infiltrate on day 5 does not have treatment failure — they are following the expected course.

Discharge criteria for hospitalized pneumonia (PORT/PSI criteria or clinical stability criteria) include: temperature below 37.8°C, heart rate below 100, respiratory rate below 24, systolic BP above 90, oxygen saturation above 90% on room air or baseline supplemental oxygen, ability to maintain oral intake, and normal mental status. Meeting these criteria — not radiographic clearance — determines readiness for discharge.

Treatment failure is defined by clinical deterioration — not by persistent radiographic findings or slow symptom resolution. The distinction is critical because the management of true treatment failure (broadening coverage, investigating for complications, considering non-infectious mimics) is very different from the management of expected slow recovery (reassurance, continued current therapy).

Clinical deterioration that defines treatment failure includes: worsening hypoxemia (increasing oxygen requirements), hemodynamic instability (hypotension, tachycardia), failure to defervesce by 72 hours of appropriate antibiotic therapy, new or worsening respiratory failure, or development of complications (empyema, lung abscess, bacteremia).

The 72-hour threshold is clinically important. Changing antibiotics within the first 48–72 hours because the patient "still has a fever" is premature unless there is clinical deterioration or a specific microbiological reason to change. Most patients with pneumonia will still have fever at 48 hours — this is expected, not failure.

When true treatment failure occurs at 72 hours or beyond, the evaluation should be systematic: review the initial antibiotic choice and dose, obtain blood cultures and sputum culture if not already done, consider CT chest to evaluate for complications (empyema, lung abscess, necrotizing pneumonia), and consider bronchoscopy if the diagnosis is uncertain.

When a patient with pneumonia is not responding to treatment, the differential falls into four categories: resistant or atypical organisms, complications of pneumonia, non-infectious mimics, and host factors.

Resistant or atypical organisms: MRSA pneumonia (particularly post-influenza or in patients with skin/soft tissue MRSA history), Pseudomonas aeruginosa (in patients with structural lung disease, bronchiectasis, or recent hospitalization), drug-resistant Streptococcus pneumoniae, and atypical organisms not covered by the initial regimen (Legionella, Mycoplasma, Chlamydophila). Legionella pneumonia in particular can cause severe, progressive pneumonia that does not respond to beta-lactam monotherapy — it requires a macrolide or fluoroquinolone.

Complications of pneumonia: parapneumonic effusion or empyema (requires drainage — antibiotics alone are insufficient), lung abscess (requires prolonged antibiotic therapy and sometimes drainage), and necrotizing pneumonia (requires CT for diagnosis and often surgical consultation).

Non-infectious mimics: organizing pneumonia (cryptogenic or drug-induced — responds to corticosteroids, not antibiotics), eosinophilic pneumonia, pulmonary vasculitis, alveolar hemorrhage, and malignancy. These conditions can present with radiographic infiltrates and systemic symptoms that mimic infectious pneumonia. Bronchoscopy with bronchoalveolar lavage is the key diagnostic procedure when a non-infectious mimic is suspected.

Host factors: immunosuppression (HIV, chemotherapy, high-dose corticosteroids) impairs the response to infection and may require broader coverage or antifungal therapy. Aspiration pneumonia in patients with dysphagia or altered mental status may require anaerobic coverage. Underlying malignancy causing post-obstructive pneumonia will not resolve until the obstruction is addressed.

Routine follow-up chest X-ray at 6–8 weeks after pneumonia is recommended for patients at risk for underlying malignancy — particularly smokers above age 50 and patients with recurrent pneumonia in the same location. The purpose is to confirm radiographic clearance and exclude an underlying mass that may have caused post-obstructive pneumonia.

A persistent infiltrate at 6–8 weeks in a patient who has clinically recovered warrants CT chest to evaluate for an underlying mass, bronchiectasis, or organizing pneumonia. A persistent infiltrate in a patient who has not clinically recovered should prompt earlier evaluation.

Routine follow-up CXR is not indicated in young, healthy patients with uncomplicated CAP who have fully recovered clinically. The yield of finding an underlying abnormality in this population is low, and the radiation exposure and cost are not justified.

Recurrent pneumonia in the same anatomic location is a red flag for an underlying structural abnormality — bronchial obstruction by tumor, foreign body, or mucus plug, or bronchiectasis. CT chest and bronchoscopy should be considered after the second episode in the same location.

Parapneumonic effusion occurs in approximately 40% of bacterial pneumonias. Most are simple (uncomplicated) and resolve with antibiotic treatment alone. A subset progresses to complicated parapneumonic effusion or empyema, which requires drainage.

The decision to drain is based on pleural fluid analysis: pH below 7.2, glucose below 60 mg/dL, LDH above 1000 IU/L, or positive Gram stain or culture indicates a complicated effusion requiring drainage. A frank empyema (pus in the pleural space) always requires drainage regardless of pH or glucose.

Failure to drain an empyema is a common cause of apparent antibiotic treatment failure. A patient with pneumonia who is not improving despite appropriate antibiotics should have a chest X-ray or CT to evaluate for a parapneumonic effusion. If an effusion is present, thoracentesis with fluid analysis is essential.

Drainage options include thoracentesis (for small, free-flowing effusions), chest tube (for larger or loculated effusions), and video-assisted thoracoscopic surgery (VATS) for complex, loculated empyemas that do not respond to tube drainage. Intrapleural fibrinolytics (tPA + DNase) can help break down loculations in complex empyemas.